August 2026
- Obstructive Hypertrophic Cardiomyopathy
- Doctor’s Dirty Little Secret — The Cost of Silence
- Phase 2b Trial of a NaV1.8 Inhibitor for Acute Pain
- Cross-Correction in HSC Gene Therapy for Metachromatic Leukodystrophy
- Case 22-2026: A 37-Year-Old Woman with Persistent Nasal Ulceration
- T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
- Transdermal Estradiol Patches in Prostate Cancer
- Sex Hormone Influences on Cardiovascular Risk
- LDL Cholesterol Targeting in Cardiovascular Disease
- Milwaukee Shoulder Syndrome
- Pregnancies in Patients with Autoimmune Disease Receiving CAR T-Cell Therapy
- The Inequality–Pandemic Cycle — Rethinking Preparedness
- iEvac-Z, an Inactivated Ebola Vaccine — Phase 1 Study in Japan
- Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment
- Pulsatile Liver in Severe Tricuspid Regurgitation
- The Paradox of Medical Aid in Dying
- Medical Standards by Federal Fiat
- Braking Bad News
- Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines
- Cardiotoxic Effects and Microdystrophin Expression after Gene Therapy for DMD
- Crew Resource Management — Navigating AI’s Automation Paradox
- Andes Virus — A Clinical Review
- A Regional Measles Outbreak — South Carolina, 2025–2026
- Platelet-Activating Anti–Platelet Factor 4 Disorders
- Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty
- Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression
- Ebola at 50 — Lessons for Outbreak Response and Preparedness
- Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609.
- Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia
- Long-Acting Treatment and Advanced HIV Disease — Addressing a Public Health Priority
- Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026
- Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
- The Social Contract of Bundibugyo Ebola Isolation
- Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
- Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema
- Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock
- Vasopressors or Fluids in Early Septic Shock
- Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease
- Carbocisteine or Hypertonic Saline for Acute Respiratory Failure
- Conservative Oxygen for Unresponsive Patients after Cardiac Arrest
- Survodutide Once Weekly for the Treatment of Adults with Obesity
- Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
- Finerenone in Persons with Chronic Kidney Disease without Diabetes
- Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica
- Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting
- Obexelimab for the Treatment of IgG4-Related Disease
- Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease
- Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer
- Perioperative Apalutamide in High-Risk Localized Prostate Cancer
- A Watershed Moment in the Perioperative Treatment of Prostate Cancer